Revising the international index of erectile function--letter to the editor regarding 'IIEF-15: unsuitable for assessing erectile function of young men?'.

摘要

We would like to commend the authors for an excellent review and summary of female sexual dysfunction in women. However, we feel compelled to point out that the chart on page 325 is incomplete. Under the heading of vulvar vaginal atrophic changes, local estrogen is discussed and described as formulated as a vaginal ring or tablet. The omission of local vaginal creams is unfortunate for many reasons. Creams, both Premarin? (New York, NY, USA) and Estrace cream (Warner Chicott; Rockaway, NJ, USA), have been the primary form of local estrogen treatment for vulvar vaginal atrophic change for almost a century. Further, in November 2009, Premarin vaginal cream became the first and only Food and Drug Administration (FDA)-approved medication for the treatment of moderate to severe dyspareunia. This landmark approval, the first FDA-approved treatment for a female sexual disorder, was not cited in major headlines or publicity.